Skip to main content

Hot Stocks: VICL, MAS, BCS, PGH, MNTA

New York, NY -- (SBWIRE) -- 11/12/2012 -- Vical Incorporated (NASDAQ:VICL) shares declined 2.61% and closed at $2.98. The company announced the release of animal data at a melanoma conference documenting the benefits of combining the company's Allovectin immunotherapy with anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies, which are emerging immunotherapies for metastatic melanoma. The company also announced a new publication1 supporting Allovectin®'s proposed mechanisms of action. Read the full press release at http://www.sbwire.com/press-releases/sbwire-179600.htm
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.